Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2001

View Archived Issues

Hemosol provides update on company progress

FDA review period for Remodulin NDA extended

Novazyme's MPS I therapy receives orphan drug designation

ISAtx-247 entering or soon to enter phase II trials for several indications

SIGA Technologies reaches milestone in novel antiinfective agent alliance with Wyeth-Ayerst

Cell Genesys commences phase I/II trial of high-potency GVAX

Clinical evaluation of antiarrhythmic agent RSD-1235 begun by Nortran

Promising efficacy and safety profile reported for DMP-450 at 24 weeks in ongoing phase I/II trial

Potent anti-RSV compound R-170591 characterized at Antiviral Research meeting

Newly synthesized PDE5 inhibitor is more potent and selective than sildenafil

First patient dosed in pivotal trial of Onyx LES for aneurysms

Lipid-lowering effects of FPFS-410 characterized in animal studies

Idun and Abbott extend anticancer alliance for additional year

Phase III trial begins for Atrix acne therapy

Apligraf marketing application submitted to EMEA

Novel antioxidant A-2757 effective in animal models of hepatic and renal injury

DAB-1059, an inhibitor of EGF receptor tyrosine kinase with nanomolar potency and antitumor activity

Italian researchers discover new taxane derivative with antiangiogenic properties

Antiangiogenic and antitumor effects demonstrated in mice for new VEGF RTK inhibitor AG-13925

Promising preclinical findings support further development of Zorex for herpesvirus infections

Antitumor agent with excellent oral activity revealed by Daiichi at recent Japanese meeting

Pharmacological characterization of the potential new prokinetic drug KF-66854

Heterocyclic PGI2 agonists in the Fujisawa pipeline

Boehringer Ingelheim claims indolinone kinase inhibitors with antiproliferative activity

Novel antitumor agent produced by Streptomyces

Chugai presents new antiandrogenic agents useful in prostate cancer, etc.

Triterpenes with ACAT-inhibitory activity designed at Pola

Mitochondrial function activators under development at Takeda

Inhibitors of sPLA2 described in recent patent literature by Shionogi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...